AML

Joint Comments on Two NIH Exclusive Licenses to CAR Therapy to Vor Biopharma and Senti Bio

Posted on by KEI Staff

On June 15, 2020, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatments (UACT) submitted joint comments to the National Institutes of Health regarding two prospective exclusive patent licenses: “Prospective Grant of an Exclusive Patent License: Development and… Continue Reading →

2018: NIH Prospective Grant of an Exclusive Patent License to ElevateBio for CAR T cancer treatment

Posted on by KEI Staff

The following are comments by KEI, UACT, Social Security Works, HealthGap, Public Citizen, Dr. Ophira Ginsbug and James Love on an NIH proposed exclusive license for patents on a CAR T technology for “Treatment of FMS-Like Tyrosine Kinase 3 (FLT3)… Continue Reading →